QCI Interpret for Oncology
Going beyond: Molecular evidence for off-label therapy use
117 views
Kathryn Bungartz, Ph.D., Associate StaffField Application Scientist, QIAGEN Digital Insights explains
•Using molecular pathways to expand therapy options
•Identifying evidence-based therapy options for cancer patients for whom there is no on-label therapy
•Providing confidence with expert-curated, oncologist-reviewed treatment strategies
•Using molecular pathways to expand therapy options
•Identifying evidence-based therapy options for cancer patients for whom there is no on-label therapy
•Providing confidence with expert-curated, oncologist-reviewed treatment strategies
Related videos
QCI Interpret for Oncology
Confidence and trust: Deliver valuable clinical insights with high-quality knowledge
Ben Turner, Director of Bioinformatics Enterprise Solutions, QIAGEN Digital...
QCI Interpret for Oncology
Generate oncologist-ready clinical reports from comprehensive panels
Ruth Burton, Ph.D., Clinical Application Specialist, QIAGEN Digital Insights...
QCI Interpret for Oncology
Gaining insights with transcriptomic profiling and mechanistic modeling
In this webinar, Moritz Schütte, head of next-generation sequencing data...
QCI Interpret for Oncology
QCI Interpret One: Oncology variant interpretation just got more precise
Competing to offer a comprehensive genomic profiling service for solid or...